- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775800
Treatment Modification to Reduce Symptom Burden in Hemodialysis
September 25, 2018 updated by: The Rogosin Institute
Treatment Modification and Symptom Burden in High-Risk Dialysis Patients
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing.
This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis.
For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects.
Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- The Rogosin Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- hemodialysis patient
- transplant ineligible
Exclusion Criteria:
- dementia
- unable to answer questionnaires for any reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment modification
Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
|
|
No Intervention: Usual care
Patients will receive the usual hemodialysis care with no modifications
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Recruited, Consented, Randomized and Completed
Time Frame: Each participant was assessed for 6 weeks; total recruitment period was 15 months
|
Each participant was assessed for 6 weeks; total recruitment period was 15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Burden
Time Frame: Baseline and 6 weeks
|
Number of symptoms in past week as measured by the Dialysis Symptom Index
|
Baseline and 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Nathaniel Berman, M.D., The Rogosin Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
January 16, 2013
First Submitted That Met QC Criteria
January 22, 2013
First Posted (Estimate)
January 25, 2013
Study Record Updates
Last Update Posted (Actual)
October 9, 2018
Last Update Submitted That Met QC Criteria
September 25, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1207012494
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
University of KansasCompletedEnd-Stage Renal Disease
-
Eisai Co., Ltd.CompletedEnd-Stage Renal DiseaseJapan
Clinical Trials on Treatment modification
-
Yair Bar-HaimGeha Mental Health CenterCompleted
-
Roseli ShavittCompleted
-
Tel Aviv UniversityCompletedAttention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)Attention Bias Modification Treatment (ABMT)Israel
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedWeight Loss | Binge Eating | Weight Gain PreventionUnited States
-
Drexel UniversityActive, not recruitingImpulsive Behavior | Overweight or Obesity | Overweight Adolescents | OvereatingUnited States
-
Hospital de Clinicas de Porto AlegreUnknownGeneralized Anxiety Disorder | Social Anxiety Disorder | Separation Anxiety DisorderUnited States, Australia, Brazil, Israel
-
Tel Aviv UniversityCompleted
-
Diakonie Kliniken ZschadraßCharite University, Berlin, Germany; Chemnitz University of TechnologyCompleted
-
Humboldt-Universität zu BerlinCompletedObsessive-Compulsive DisorderGermany
-
Hospital de Clinicas de Porto AlegreUnknownGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic DisorderBrazil